Research & Pharma Services

Innovative assays that can help answer your most challenging genomic questions, comprehensively

Why GTC:

- Unique menu offering numerous innovative NGS applications
- Rapid turn-around time
- Project scalability
- Robust AI and deep learning platform to help with report interpretation
- World class expertise in both hematologic cancers, solid tumors and immuno-oncology
- Access to over 50k data records

Genomic Testing Cooperative is a unique provider of biomarker data through our comprehensive genomic profiling of DNA and RNA.

GTC's testing is standardized using next gen sequencing to provide the most omplete picture of a patient's tumor biology and actionable biomarkers. We have data on both solid and hematologic neoplasms. Our testing and collaborations allow us to provide different data points than other laboratories that is extremely valuable and rare.

Types of data we can provide

Biomarker data

- FDA-approved
- Standard of care
- Clinical evidence
- Biological relevance
- Other

Lab data

- ICD 10 codes
- Sample type
- Body site
- Order date
- QNS/TNP info

Clinical data*

- Presentation data
- Outcome data
- Treatment data
- Lines of therapy
- Demographic info

* Limited to a subset of patient samples

Areas where we collaborate

- Clinical trial enrollment
- Biomarker frequency
- Custom data solutions

- **Retrospective trials - Prospective trials - CDX**
- **Comprehensive DNA/RNA sequencing applications paired with AI analysis tools**
- **IHC Assays**

GENOMIC® TESTING COOPERATIVE

Genomic Testing Cooperative, LCA
175 Technology Dr, #100, Irvine, CA 92618
Tel: 1-949-540-9421 | Fax: 1-949-301-9719
Website: genomictestingcooperative.com
e-mail: gtc@genomictestingcooperative.com

Available Tests	GTC-Solid Tumor Profile PLUS™	Liquid Trace™: Solid Tumor	GTC-Solid Tumor Profile™
Genes	434/>1600	284/>1600	434
Indications	All solid tumors: Detect known (ALK, RET, ROS1, NTRK, etc.) and novel fusions, Exon skipping (MET exon 14), PD-L1 levels, ERBB2 (low HER2) cut-offs and alternative splicing. Chromosomal translocations and amplifications. Viral HPV testing. T- & B-cell clonality analysis HLA genotyping	All solid tumors: Detect known (ALK, RET, ROS1, NTRK, etc.) and novel fusions, Exon skipping (MET exon 14), PD-L1 levels, ERBB2 (low HER2) cut-offs and alternative splicing. Chromosomal translocations and amplifications. Viral HPV testing T- & B-cell clonality analysis HLA genotyping, TMB, MSI, HRD	All solid tumors: Full exon sequencing in 434 genes includes mutations, indels, copy number variation and chromosomal structural abnormalities, TMB, MSI, HRD, HRR
Sample Type	FFPE	Peripheral Blood	FFPE
Sample Requirements	1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	Peripheral blood: 8-10 mL. EDTA tube preferred*	1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported	DNA + RNA	DNA + RNA	DNA



Viral HPV, EBV testing

Available Tests	GTC-Hematology Profile PLUS™	Liquid Trace™: Hematology	GTC-Hematology Profile™
Genes	284/>1600	284/>1600	284
Indications	All hematologic neoplasms including lymphomas, myelomas, and leukemias Includes IgVH Chromosomal abnormalities, translocations and gene amplifications Viral EBV testing T- & B-cell clonality analysis HLA genotyping	All hematologic neoplasms including lymphomas, myelomas, leukemias, VEXAS syndrome, and EBV Chromosomal abnormalities, translocations and gene amplifications Replacement for bone marrow aspirations and biopsy, Monitoring therapy and response, Detection of minimal residual disease (MRD), T- & B-cell clonality analysis HLA genotyping, TMB, MSI, HRD	Detects various abnormalities in hematologic neoplasms including: Chromosomal abnormalities, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), Distinguish Clonal Hematopoiesis of Indeterminate Potential (CHIP) VEXAS Disease
Sample Type	Bone marrow, Peripheral blood, Fresh tissue	Peripheral Blood	Bone marrow, Peripheral blood, Fresh tissue
Sample Requirements	Bone marrow: 2mL. Peripheral blood: 5 mL. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative	Peripheral blood: 8-10 mL. EDTA tube preferred*	Bone marrow: 2mL. Peripheral blood: 5 mL. EDTA tube preferred FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative
Results Reported	DNA + RNA	DNA + RNA	DNA

Solid Tumor | Hematologic Malignancies | Liquid Biopsy | Molecular and Genomic Assays | AI Algorithms | IHC | Customized Assays

Solid Tumor Profile Plus

- Pan tumor assay focused on solid tumors
- 434 DNA genes and >1600 RNA genes
- Covers major biomarkers like MSI, TMB, HRD and more
- Detect chromosomal structural changes
- Reliable fusion detection,
- Alternative splicing,
- Gene expression
- Exon skipping
- Immune profiling
- HLA expression and genotyping
- T-cell & B-cell clonality analysis

Liquid Trace™ (cfDNA and cfRNA)

- Pan tumor assay for both solid tumors and hematologic malignancies
- Full gene sequences of 284 DNA genes and more than 1600 RNA genes
- Reliable fusion detection of both known and novel genes
- Covers numerous biomarkers like HRR, PD-L1, HER2 and more
- Includes viral DNA testing for HPV and EBV
- HLA expression and genotyping
- Tumor mutation burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD)

Hematology Profile Plus

- Pan tumor assay focused on hematologic malignancies
- 284 DNA genes and >1600 RNA genes
- Classify all subtypes of leukemia, lymphomas, myelomas, MDS, VEXAS, CHIP and more
- AML
- CMML
- Detect chromosomal structural changes and chromosomal rearrangements
- Gene expression
- HLA expression and genotyping
- T-cell & B-cell clonality analysis

AI Algorithms

GTC offers several world class AI software's available for your research and clinical trial projects with multiple publications in top journals. Our AI tools can assist with:

- Picking the correct cut-offs for biomarkers
- Identify responders from non-responders
- Other critical testing algorithms
- Our AI software's can be customized and tuned to work with any assay

Immunohistochemistry (IHC)

GTC has added Immunohistochemistry (IHC) testing to complement our next-gen sequencing capabilities. We can bring up an antibody or assay to use in your research project. Our NGS can also do a comparison of the IHC and NGS findings.
Capabilities include:

- Histology
- Custom IHC
- Image analysis

Global capabilities for clinical trials through our partnership with Sysmex Inostics

Customized Assays

Genomic Testing Cooperative (GTC) offers all types of sequencing services for research projects and clinical trials. We provide a wide range of capabilities from Sanger sequencing to next generation sequencing. All projects are performed in our CAP and CLIA accredited laboratory by Clinical Laboratory Specialists (CLS).
We can provide several standard tumor profiling panels or collaborate on custom panel development for projects in the field of oncology and immuno-oncology. All studies have optional bioinformatics support and access to our deep learning tools or GTC can deliver raw data files for interpretation with your own tools.

Types of Pharma and Research Support Services We Offer:

- Next-gen sequencing
- Sanger sequencing
- RNA-analysis
- Solid tumor research
- Hematology research
- Liquid biopsy
- Custom assay development
- AI analysis
- Bioinformatics support
- CDx development
- Biomarker discovery

GTC has a collaboration agreement in place with laboratories to perform flow cytometry and can perform additional services and capabilities beyond sequencing and IHC if your project requires it.

GENOMIC TESTING COOPERATIVE®